| Autologous BM-MNC [16] |
Safety Efficacy |
15 in study group,19 in control group. |
24 hours after STEMI. |
8.37 × 106 |
LVEDV, LVESV, LVEF by echocardiography (biplane Simpson method – apical two- and four-chamber). |
Achieved safety.Nine patients in study group (60%) achieved an improvement in LVEF > 10% at 12-month follow-up. |
| Autologous BM-MSC [14] |
Safety Efficacy |
14 in study group,12 in control group. |
1 month after STEMI. |
7.2 ± 0.9 × 107 |
LVEF by SPECT and echocardiography. |
Achieved safety.Improvement in LVEF in study group at 4-month follow-up (8.8% vs. 4.8%, p=0.031 by SPECT and 9% vs. 5.3%, p=0.023 by echocardiography). |
| Autologous BM-MNC [18] |
Efficacy |
51 in early study group44 in late study group,54 in control group. |
Early: 5–7 days after STEMILate: 3–4 weeks after STEMI. |
5 × 107 – 5 × 108 |
GLS and GCS by cardiac magnetic resonance. |
None of time related treatment proved an improvement in cardiac parameters. |
| Autologous BM-MNC [17] |
Efficacy |
66 in study group,55 in control group. |
6–9 days after STEMI. |
100 × 106 |
LVEF, LVEDV, LVESV, infarct size by cardiac magnetic resonance. |
Study and control group had similar results at baseline, at 6-month follow-up and between times. |
| Autologous BM-MSC [10] |
Safety Efficacy |
21 in study group,22 in control group. |
14.07 +/−9.53 days after STEMI. |
3.31 ± 1.7 × 106 |
LVEF, LVEDV, LVESV by echocardiography (Simpson method) at 12 months and myocardial perfusion and metabolic activity by SPECT at 6-month follow-up. |
Achieved safety.No statistically significant difference (p>0,05) between study and control group regarding LVEF, LVEDV and LVESV at 12 months or myocardial perfusion and metabolic defect index at 6-month follow-up. |
| Allogenic CSC [19] |
Safety Efficacy |
33 in study group16 in control group. |
Days 5–7 after STEMI. |
35 × 106 |
Infarct size, LVEF, LVEDV, LVESV and wall motion score by cardiac magnetic resonance. |
Safety was the primary endpoint, and it didn’t reveal any major cardiac adverse events or deaths at 6- and 12-month follow-up. No significant differences in assessed parameters between the groups at baseline and follow-up times. |
| Allogenic CDC [20] |
Safety Efficacy |
90 in study group44 in placebo group. |
4 weeks to 12 months after STEMI. |
2.5 × 106 |
Infarct size, LVEDV, LVESV, LVEF by cardiac magnetic resonance. |
Safety endpoint was achieved.There was no significant difference in infarct size between groups at 6-month follow-up (p=0.51). Yet there was a reduction in LVEDV (p=0.02) and LVESV (p=0.02) at 6 month follow-up in favor of study group. |
